基本信息
views: 11
Career Trajectory
Bio
Research Synopsis
Innovation for optimized detection and analysis of circulating tumor DNA (ctDNA). Analysis of ctDNA has the potential to revolutionize cancer detection and management. The Bratman Lab is a persistent source of innovation in ctDNA and other 'liquid biopsy' technologies. This includes methods for analysis of genetic, microbial, and epigenetic aberrations in circulating DNA. We develop novel molecular biology, sequencing, and bioinformatics approaches with the ultimate goal of clinical utility and adoption. We are also interested in the biology of circulating DNA and ctDNA release.
Personalized cancer medicine for head and neck cancer (HNC). As a radiation oncologist who treats patients with HNC, Dr. Bratman pursues a research agenda aimed at benefiting HNC patients. Many HNC patients endure poor outcomes despite treatment regimens such as chemo-radiotherapy that can cause significant toxicities. Thus, novel therapeutic strategies and innovative biomarkers are needed to improve management of this disease. The Bratman Lab is developing new radiation sensitizers with the goal of more tailored, tolerable, and effective treatment. The group is also pursuing molecular biomarkers to enable earlier diagnosis of cancer, risk stratification, and treatment individualization.
Innovation for optimized detection and analysis of circulating tumor DNA (ctDNA). Analysis of ctDNA has the potential to revolutionize cancer detection and management. The Bratman Lab is a persistent source of innovation in ctDNA and other 'liquid biopsy' technologies. This includes methods for analysis of genetic, microbial, and epigenetic aberrations in circulating DNA. We develop novel molecular biology, sequencing, and bioinformatics approaches with the ultimate goal of clinical utility and adoption. We are also interested in the biology of circulating DNA and ctDNA release.
Personalized cancer medicine for head and neck cancer (HNC). As a radiation oncologist who treats patients with HNC, Dr. Bratman pursues a research agenda aimed at benefiting HNC patients. Many HNC patients endure poor outcomes despite treatment regimens such as chemo-radiotherapy that can cause significant toxicities. Thus, novel therapeutic strategies and innovative biomarkers are needed to improve management of this disease. The Bratman Lab is developing new radiation sensitizers with the goal of more tailored, tolerable, and effective treatment. The group is also pursuing molecular biomarkers to enable earlier diagnosis of cancer, risk stratification, and treatment individualization.
Research Interests
Papers共 369 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
crossref(2024)
CANCER DISCOVERYno. 6 (2024): 1048-1063
International Journal of Radiation Oncology*Biology*Physicsno. 1 (2024): e2
Biochemistry and Cell Biologyno. 4 (2024): 291-298
G. Liu, J. Zhang,Y. Wang, J. Burgener, O. Hall, S. Y. Shen,M. Pienkowski,S. H. Huang, E. Sosa, A. Polio,S. B. Goldberg, P. Mazzone,
International Journal of Radiation Oncology*Biology*Physicsno. 1 (2024): E3-E4
Geoffrey Liu, Jun Min, Yarong Wang,Justin Burgener, Ben Brown, Karen Budhraja, Junjun Zhang, Owen Hall,Shu Yi Shen,Martha Pienkowski,Shao Hui Huang,Laurie Ailles,
Cancer Researchno. 6_Supplement (2024): 2427-2427
crossref(2024)
crossref(2024)
crossref(2024)
Load More
Author Statistics
#Papers: 368
#Citation: 10924
H-Index: 37
G-Index: 103
Sociability: 7
Diversity: 0
Activity: 5
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn